Results 21 to 30 of about 663,256 (217)

Prognostic factors and survival study in high-grade glioma in a hospital in Lima, Peru

Revista de la Facultad de Medicina Humana, 2020
Introduction: Gliomas are primary tumors of the central nervous system. They are classifiedfrom grade I-IV, with high grade III and IV being the most frequent and with poor prognosis. Objective: To determine the prognostic factors of survival in patients
Paul Méndez-Aguilar, Victor Juan Vera-Ponce   +1 more
doaj   +1 more source

Outcome of Primary CNS Lymphoma; A Retrospective Analysis

Asian Pacific Journal of Cancer Care, 2022
Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi, Daniyaal Ahmed, Sobia Sawani, Munira Moosajee   +3 more
doaj   +1 more source

Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Cancer Treatment and Research Communications, 2021
Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj   +1 more source

The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Cancer Cell International, 2021
Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini, Ali Nikkhah, Amir Sotudeh, Marziyeh Alizadeh Zarei, Fatemeh Izadpanah, Hossein Nikzad, Hamed Haddad Kashani   +6 more
doaj   +1 more source

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

Breast, 2021
Background: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of ...
I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu   +6 more
doaj   +1 more source

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BMC Cancer, 2021
Background An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms.
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen   +5 more
doaj   +1 more source

MRI radiomics predicts progression-free survival in prostate cancer

Frontiers in Oncology, 2022
ObjectiveTo assess the predictive value of magnetic resonance imaging (MRI) radiomics for progression-free survival (PFS) in patients with prostate cancer (PCa).Methods191 patients with prostate cancer confirmed by puncture biopsy or surgical pathology were included in this retrospective study, including 133 in the training group and 58 in the ...
Yushan Jia, Shuai Quan, Jialiang Ren, Hui Wu, Aishi Liu, Yang Gao, Fene Hao, Zhenxing Yang, Tong Zhang, He Hu   +9 more
openaire   +3 more sources

Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer – a review of the literature from a developing country perspective

Contemporary Oncology, 2016
We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski, Violetta Sulżyc-Bielicka   +1 more
doaj   +1 more source

Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review

European Journal of Medical Research
Background Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options.
Elyar Mahboubi, Mahdieh Mondanizadeh, Amir Almasi-Hashiani, Elham Ghasemi   +3 more
doaj   +1 more source

Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study

Experimental Hematology & Oncology
Diagnosis-to-treatment interval (DTI) is an important prognostic factor in patients with newly diagnosed aggressive lymphomas, however the impact of DTI on outcomes in marginal zone lymphoma (MZL) is unknown.
Narendranath Epperla, Geoffrey Shouse, Natalie S. Grover, Pallawi Torka, Kaitlin Annunzio, Marcus Watkins, Andrea Anampa-Guzmán, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J. Olszewski   +13 more
doaj   +1 more source